Radioimmunotherapy (RIT) with 131l-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

2523 Background: The extradomain B of fibronectin (EDBF) is a promising target for cancer therapies due to its selective expression in newly formed blood vessels of SC and lymphomas. L19 is a human...